PI3KD/V-IN-01 exhibited better anti-proliferative activity against AML, CLL and Burkitt lymphoma cell lines than known selective PI3Kδ and Vps34 inhibitors. Here, PIK3C3 is linked to B-cell chronic lymphocytic leukemia.